Skip to content

Solifenacin

Vesicare, Vesicare Ls (solifenacin) is a small molecule pharmaceutical. Solifenacin was first approved as Vesicare on 2004-11-19. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. The pharmaceutical is active against muscarinic acetylcholine receptor M3 and muscarinic acetylcholine receptor M2. In addition, it is known to target muscarinic acetylcholine receptor M4, muscarinic acetylcholine receptor M5, and muscarinic acetylcholine receptor M1. Vesicare's patent is valid until 2031-05-18 (FDA).
Trade Name Vesicare, Vesicare Ls
Common Name Solifenacin
Indication overactive urinary bladder, urge urinary incontinence
Drug Class Muscarinic receptor antagonists
Solifenacin
Get full access now